Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 11, 2023, titled "Zydus receives final approval from the USFDA for Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg".
Press Release Mar 15 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Olanzapine Orally Disintegrating Tablets in various strengths. These tablets are used to treat mental and mood conditions such as schizophrenia and bipolar disorder. The manufacturing will take place at the company's facility in Moraiya, Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 09 2023
- Press Release Mar 07 2023
- Press Release Mar 03 2023
- Press Release Mar 02 2023
- Press Release Feb 28 2023
Later from Zydus Lifesciences
- Press Release Mar 21 2023
- Press Release Mar 24 2023
- Press Release Mar 25 2023
- Press Release Mar 28 2023
- Press Release Apr 06 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences